Lexeo Therapeutics Ownership | Who Owns Lexeo Therapeutics?

Lexeo Therapeutics Ownership Summary

Lexeo Therapeutics is owned by 127.64% institutional investors, 0.46% insiders. Frazier life sciences management is the largest institutional shareholder, holding 13.36% of LXEO shares.

LXEO Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Lexeo Therapeutics	127.64%	0.46%	-28.10%
Sector	Healthcare Stocks	488.30%	11.08%	-399.38%
Industry	Biotech Stocks	307.10%	11.11%	-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Frazier life sciences management	4.42M	13.36%	$17.79M
Balyasny asset management	4.01M	12.11%	$16.12M
Affinity asset advisors	3.59M	10.84%	$14.43M
Vestal point capital, lp	3.23M	9.75%	$12.98M
Blackrock funding, inc. /de	1.83M	5.52%	$7.35M
Omega fund management	1.18M	3.58%	$4.76M
Blackstone	1.12M	3.40%	$4.52M
D1 capital partners	978.65K	2.96%	$3.93M
Ally bridge group (ny)	867.30K	2.62%	$3.49M
Point72 asset management	647.88K	1.96%	$2.60M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Omega fund management	1.18M	3.08%	$4.76M
Ally bridge group (ny)	867.30K	2.90%	$3.49M
Affinity asset advisors	3.59M	1.97%	$14.43M
Frazier life sciences management	4.42M	0.71%	$17.79M
Caxton	17.33K	0.71%	$69.67K
Vestal point capital, lp	3.23M	0.68%	$12.98M
Ikarian capital	550.03K	0.42%	$2.21M
Dafna capital management	378.08K	0.42%	$1.52M
Siren	603.43K	0.13%	$2.43M
Adar1 capital management	145.11K	0.09%	$583.34K

Top Buyers

Holder	Shares	% Assets	Change
Balyasny asset management	4.01M	0.02%	4.01M
Frazier life sciences management	4.42M	0.71%	3.47M
Affinity asset advisors	3.59M	1.97%	2.11M
Vestal point capital, lp	3.23M	0.68%	2.09M
Ally bridge group (ny)	867.30K	2.90%	867.30K

Top Sellers

Holder	Shares	% Assets	Change
Eventide asset management	-	-	-1.23M
Novo	-	-	-1.12M
Ra capital management	-	-	-546.55K
Point72 asset management	647.88K	0.01%	-450.26K
Altium capital management lp	-	-	-405.00K

New Positions

Holder	Shares	% Assets	Change	Value
Balyasny asset management	4.01M	0.02%	4.01M	$16.12M
Ally bridge group (ny)	867.30K	2.90%	867.30K	$3.49M
Palumbo wealth management	56.30K	0.07%	56.30K	$226.34K
Quadrature capital	29.78K	0.00%	29.78K	$120.31K
Susquehanna portfolio strategies	22.26K	0.00%	22.26K	$89.48K

Sold Out

Holder	Change
Rothschild investment	-20.00
Coldstream capital management	-93.00
Nelson, van denburg & campbell wealth management group	-185.00
Gamma investing	-245.00
Russell investments group	-416.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2025	89	2.30%	42,266,176	54.77%	127	1.88%	54	35.00%	15	-34.78%
Mar 31, 2025	91	4.60%	28,007,979	-3.59%	84	1.10%	42	-26.32%	23	109.09%
Dec 31, 2024	89	32.84%	29,519,159	-0.73%	89	1.10%	59	13.46%	11	37.50%
Sep 30, 2024	67	17.54%	29,735,114	11.93%	89	1.39%	52	33.33%	8	-38.46%
Jun 30, 2024	57	5.56%	26,566,626	14.91%	80	1.18%	39	-15.22%	13	160.00%

Recent Insider Transactions

Date	Name	Role	Activity	Value
Oct 17, 2025	See Tai Sandi	Chief Development Officer	Sell	$34.35K
Oct 17, 2025	See Tai Sandi	Chief Development Officer	Sell	$420.68
Oct 17, 2025	Robertson Jenny	Chief Legal Officer	Sell	$31.15K
Oct 17, 2025	Robertson Jenny	Chief Legal Officer	Sell	$382.44
Oct 17, 2025	Otero Jose Manuel	Chief Technical Officer	Sell	$18.68K

Insider Transactions Trends

Date	Buy	Sell
2025 Q4	-	10
2025 Q3	-	5
2025 Q2	-	4
2025 Q1	-	4
2024 Q4	1	3

LXEO Ownership FAQ

Who Owns Lexeo Therapeutics?

Lexeo Therapeutics shareholders are primarily institutional investors at 127.64%, followed by 0.46% insiders and -28.10% retail investors. The average institutional ownership in Lexeo Therapeutics's industry, Biotech Stocks , is 307.10%, which Lexeo Therapeutics falls below.

Who owns the most shares of Lexeo Therapeutics?

Lexeo Therapeutics’s largest shareholders are Frazier life sciences management (4.42M shares, 13.36%), Balyasny asset management (4.01M shares, 12.11%), and Affinity asset advisors (3.59M shares, 10.84%). Together, they hold 36.31% of Lexeo Therapeutics’s total shares outstanding.

Does Blackrock own Lexeo Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Lexeo Therapeutics.

Who is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested?

Omega fund management is Lexeo Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.08% of its assets in 1.18M Lexeo Therapeutics shares, valued at 4.76M$.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools